ADVERTISEMENT
The Atopic Dermatitis Pipeline
Peter Lio, MD, FAAD, is clinical assistant professor of dermatology and pediatrics at Feinberg School of Medicine at Northwestern University in Chicago, IL. In this video, Dr Lio discusses upcoming therapeutics and treatments for atopic dermatitis from his session at Society of Dermatology Physician Assistants Annual Summer Dermatology Conference 2021
Transcript
Dr Lio: There are so many exciting things for AD. This is kind of our time. There are a number of systemic agents, in fact, there are three JAK inhibitors that are, hopefully, going to be approved really, really soon. We're kind of awaiting the final word from the FDA, but abrocitinib, upadacitinib, and baricitinib, those are all, potentially, going to be game-changers. They're oral preparations, they're small molecules, very powerful anti-inflammatory treatments.
We have a couple of topical agents coming, ruxolitinib. We also have one called tapinarof, that's going to be, it looks like, initially approved in the psoriasis space. We know it's being studied for AD. Hopefully, it will be there for us soon, and some new biologics coming. Lebrikizumab and tralokinumab are both in development.
There's a whole bunch of medicines coming. I think this is great news for us as clinicians, but even better news for our patients because having more options, more competition, all of these things I think are very good. It allows us to pick the right fit for the right patient and I think it allows accessibility to be better because everyone is going to have to fight.
We know that if the medicine is too expensive or inaccessible to a patient, we can't get it. I think this gets the companies excited to say, we're going to do everything we can to get this to the people who need it.
